Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 238 participants.
Also called NCT05161741
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 238 participants
- Sponsor
- Registry
-
NCT05161741
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Pakistan
- Registry status
- Completed
Technical summary
Registry record NCT05161741. Allocation not applicable; no masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2022-11-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus
- Acronym
- RISE
- Condition
- Adverse Drug Event
- Condition
- Effect of Drug
- Condition
- Type 2 Diabetes Treated With Insulin
- Intervention (Drug)
- Insulin
- Lead sponsor
- Getz Pharma
Record details
- Record id
cardio:ct-nct05161741- Content hash
902807792a5dcf1559ee23076b5bcd3805889b83b0e4f85699bd113ca1db9ce8